search
Back to results

A Study to Assess the Efficacy of Inhaled Corticosteroid (ICS) Therapy in Moderate-Severe Bronchial Asthma

Primary Purpose

Bronchial Asthma

Status
Completed
Phase
Phase 1
Locations
Germany
Study Type
Interventional
Intervention
inhaled corticosteroid therapy
Sponsored by
Novartis
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bronchial Asthma focused on measuring markers, inflammation, optimal, sub-optimal, corticosteroid, bronchial asthma

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male and/or female moderate to severe asthmatic patients, from 18-75 years of age.
  • Moderate to severe asthma, according to the GINA guidelines, for at least one year with no exacerbations requiring hospitalization and/or oral steroids within the previous three months.
  • No concomitant lung disease or significant medical conditions
  • Fluticasone propionate 500mcg daily or greater, or equivalent (Mometsaone 800 mcg, triamcinolone 2000 mcg, Flunisolide 2000 mcg, Budesonide DPI 800 mcg, Beclomathasone HFA 500 mcg, Beclomethasone CFC 1000 mcg, Forced expiratory volume in 1 second (FEV1) at screening will be ≥ 70% of the normal predicted.
  • Evidence of asthma, demonstrated by one of the following: Historical evidence confirmed by their treating physician or Demonstration of ≥ 12% reversibility of FEV1 using a standard dose of salbutamol (up to 400 µg) within 30 minutes.
  • Female subjects of child bearing potential must be using two forms of contraception or postmenopausal women must have no regular menstrual bleeding for at least 2 years prior to inclusion.
  • Body Mass Index between 18 and 30. Body weight should be less than 100 kg.

Exclusion Criteria:

  • Smokers
  • Concomitant medications: Except for short- and long-acting β-agonists and medication which may be required to treat adverse events, all other medications, other than study drug should be avoided from screening until all of the study completion evaluations have been conducted. Paracetamol is acceptable.
  • Medical conditions: history of clinically significant drug allergy; any significant medical condition. For example, a history of any pulmonary disorder other than asthma.
  • Any surgical or medical condition which might significantly alter the distribution, metabolism or excretion of the drug.
  • Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation.
  • Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing or longer if required by local regulation.
  • Significant illness within the two weeks prior to dosing.
  • A past personal or close family medical history of clinically significant cardiac abnormalities
  • History of history of fainting, orthostatic hypotension, sinus arrhythmia, etc.
  • A known hypersensitivity to Fluticasone propionate or drugs similar to Fluticasone propionate.
  • History of immunocompromise, including a positive HIV test result.
  • A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.
  • History of drug or alcohol abuse within the 12 months prior to dosing

Other protocol-defined inclusion/exclusion criteria may apply

Sites / Locations

  • Novartis Investigative Site

Outcomes

Primary Outcome Measures

Change in inflammatory parameters in response to a decrease in ICS compared to no change in therapy after 2 and 4 weeks

Secondary Outcome Measures

Parameter/combination of parameters most sensitive to the ICS reduction
Collection of relative data to assess sample size calculations for subsequent studies

Full Information

First Posted
December 13, 2006
Last Updated
June 21, 2007
Sponsor
Novartis
search

1. Study Identification

Unique Protocol Identification Number
NCT00411567
Brief Title
A Study to Assess the Efficacy of Inhaled Corticosteroid (ICS) Therapy in Moderate-Severe Bronchial Asthma
Official Title
An Open Label Study to Assess the Utility of Measuring Markers of Inflammation, to Detect Transition From Optimal to Sub-Optimal Inhaled Corticosteroid Therapy in Moderate-Severe Bronchial Asthma
Study Type
Interventional

2. Study Status

Record Verification Date
June 2007
Overall Recruitment Status
Completed
Study Start Date
July 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Novartis

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to investigate/assess the treatment of moderate to severe asthmatics with inhaled corticosteroid.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bronchial Asthma
Keywords
markers, inflammation, optimal, sub-optimal, corticosteroid, bronchial asthma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
26 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
inhaled corticosteroid therapy
Primary Outcome Measure Information:
Title
Change in inflammatory parameters in response to a decrease in ICS compared to no change in therapy after 2 and 4 weeks
Secondary Outcome Measure Information:
Title
Parameter/combination of parameters most sensitive to the ICS reduction
Title
Collection of relative data to assess sample size calculations for subsequent studies

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and/or female moderate to severe asthmatic patients, from 18-75 years of age. Moderate to severe asthma, according to the GINA guidelines, for at least one year with no exacerbations requiring hospitalization and/or oral steroids within the previous three months. No concomitant lung disease or significant medical conditions Fluticasone propionate 500mcg daily or greater, or equivalent (Mometsaone 800 mcg, triamcinolone 2000 mcg, Flunisolide 2000 mcg, Budesonide DPI 800 mcg, Beclomathasone HFA 500 mcg, Beclomethasone CFC 1000 mcg, Forced expiratory volume in 1 second (FEV1) at screening will be ≥ 70% of the normal predicted. Evidence of asthma, demonstrated by one of the following: Historical evidence confirmed by their treating physician or Demonstration of ≥ 12% reversibility of FEV1 using a standard dose of salbutamol (up to 400 µg) within 30 minutes. Female subjects of child bearing potential must be using two forms of contraception or postmenopausal women must have no regular menstrual bleeding for at least 2 years prior to inclusion. Body Mass Index between 18 and 30. Body weight should be less than 100 kg. Exclusion Criteria: Smokers Concomitant medications: Except for short- and long-acting β-agonists and medication which may be required to treat adverse events, all other medications, other than study drug should be avoided from screening until all of the study completion evaluations have been conducted. Paracetamol is acceptable. Medical conditions: history of clinically significant drug allergy; any significant medical condition. For example, a history of any pulmonary disorder other than asthma. Any surgical or medical condition which might significantly alter the distribution, metabolism or excretion of the drug. Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation. Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing or longer if required by local regulation. Significant illness within the two weeks prior to dosing. A past personal or close family medical history of clinically significant cardiac abnormalities History of history of fainting, orthostatic hypotension, sinus arrhythmia, etc. A known hypersensitivity to Fluticasone propionate or drugs similar to Fluticasone propionate. History of immunocompromise, including a positive HIV test result. A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result. History of drug or alcohol abuse within the 12 months prior to dosing Other protocol-defined inclusion/exclusion criteria may apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis
Organizational Affiliation
Investigator site
Official's Role
Principal Investigator
Facility Information:
Facility Name
Novartis Investigative Site
City
Nuernberg
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

A Study to Assess the Efficacy of Inhaled Corticosteroid (ICS) Therapy in Moderate-Severe Bronchial Asthma

We'll reach out to this number within 24 hrs